Given that the PI3K/AKT/mTOR pathway is frequently activated in ovarian cancer and obesity, this study aimed to access the anti-tumorigenic efficacy of everolimus in ovarian cancer cells under different glucose conditions in vitro and in lean and obese mouse models of serous ovarian cancer in vivo. This evidence concerns the gene PIK3CA and ovarian carcinoma.